Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Subtyping-directed precision treatment improves therapy effectiveness for HR+/HER2− breast cancer.
• Drug susceptibility mechanisms of SNF3 identified using PDO reveal critical therapeutic insights.
• Omics features analyzed through precision treatment strategies in breast cancer open new avenues for individualized care.
• Enhanced outcomes may result from tailored therapies, highlighting the need for ongoing research in drug mechanisms.